OptimizeRx (NASDAQ:OPRX) Given Market Outperform Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $15.00 price target on the stock. A number of other brokerages also recently commented on OPRX. Royal Bank of Canada reissued an outperform rating and […]

Related Keywords

Canada ,Hong Kong ,Stifel Nicolaus ,Hong Kong Ltd ,Charles Schwab Investment Management Inc ,Royal Bank ,Optimizerx Corporation ,Nasdaq ,Nuveen Asset Management ,Barclays ,Thrivent Financial For Lutherans ,Free Report ,Moderate Buy ,Asset Management ,Financial Advisors ,Schwab Investment Management ,Kong Ltd ,Get Free Report ,Evidence Based Physician Engagement ,Care Banner ,Optimizerx Daily ,Optimizerx ,Nasdaq Oprx ,Oprx ,Computer And Technology ,Reiterated Rating ,Jmp Securities ,